

# Zynlonta (loncastuximab tesirine-lpyl)

Override(s)	Approval Duration
Prior Authorization	1 year

Medications
Zynlonta (loncastuximab tesirine-lpyl)

## APPROVAL CRITERIA

Requests for Zynlonta (loncastuximab tesirine-lpyl) may be approved if the following criteria are met:

- I. Individual has a diagnosis of progressive, relapsed or refractory large B-cell lymphoma (LBCL), including diffuse large B-cell lymphoma (DLBCL) not otherwise specified, DLBCL arising from low grade lymphoma, HIV-related diffuse large B-cell lymphomas (NCCN 2A), high-grade B-cell lymphomas, and Post-Transplant Lymphoproliferative Disorders; **AND**
- II. Individual is using Zynlonta as a single agent; **AND**
- III. Individual has received at least two prior lines of systemic therapy; **AND**
- IV. Individual has a current ECOG performance status of 0-2 (NCT03589469).

Requests for Zynlonta (loncastuximab tesirine-lpyl) may not be approved for the following:

- I. All other indications not included above; **OR**
- II. Individuals with active central nervous system (CNS) lymphoma.

## Key References:

1. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2023. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
2. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Updated periodically.
3. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
4. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2023; Updated periodically.
5. NCCN Clinical Practice Guidelines in Oncology™. © 2023 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on July 21, 2023.
  - a. B-cell Lymphomas. V4.2023. Revised June 2, 2023.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.